David Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma.
David Braun, MD, PhD
David Braun, MD, PhD, is an assistant professor of medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Articles by David Braun, MD, PhD
Renal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.
Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical data to inform their treatment approach for renal cell carcinoma.
Oncology experts examine their patient population demographics and discuss the percentage of clear cell renal cell carcinoma patients who progress to receive third-line and subsequent lines of therapy.
Renal cell carcinoma specialists continue analyzing the case of a 61-year-old patient with indolent metastatic clear cell RCC, evaluating available therapeutic options, discussing disease progression, and addressing recent changes in treatment guidelines.
Medical experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in renal cell carcinoma patients treated with immune checkpoint inhibitor and tyrosine kinase inhibitor combinations.
Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.
Medical experts examine the case of a 61-year-old male patient with a history of low-volume, indolent metastatic clear cell renal cell carcinoma, who has undergone left nephrectomy and adrenalectomy.
Renal cell carcinoma specialists analyze the case of a 59-year-old woman with RCC, focusing on the partial response observed on CT imaging four months after initiating combination therapy with nivolumab and ipilimumab.
Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.
Oncology specialists analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic renal cell carcinoma.
Renal cell carcinoma experts examines risk stratification strategies to guide their treatment approaches for a 59-year-old woman with RCC.
Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.
A panel of renal cell carcinoma experts deliberates on the treatment approach for a 59-year-old woman diagnosed with a left renal mass.